Skip to main content

Acute Spinal Cord Injury (SCI)

2
Pipeline Programs
2
Companies
2
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

TechnoPhage
TechnoPhagePortugal - Lisbon
1 program
1
Eletriptan HBr 40 mgPhase 1/21 trial
Active Trials
NCT06677229Recruiting28Est. Jun 2027
NovaGo Therapeutics
NovaGo TherapeuticsSwitzerland - Zurich
1 program
1
NG004Phase 11 trial
Active Trials
NCT06817577Recruiting21Est. Sep 2026

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
TechnoPhageEletriptan HBr 40 mg
NovaGo TherapeuticsNG004

Clinical Trials (2)

Total enrollment: 49 patients across 2 trials

NCT06677229TechnoPhageEletriptan HBr 40 mg

Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury

Start: Aug 2025Est. completion: Jun 202728 patients
Phase 1/2Recruiting

NG004 in Spinal Cord Injury Patients

Start: Dec 2024Est. completion: Sep 202621 patients
Phase 1Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 49 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.